TrialReader


PET-CT in AML for Detection of Extramedullary AML Manifestations

NCT01278069 — Completed, 93 participants, Technische Universität Dresden

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

PET-AML - Value of 18FDG-PET-CT in Patients With AML for Detection of Extramedullary AML Manifestations

RegistryNCT01278069, acronym PETAML
StatusCompleted
Study typeObservational
Enrollment93 (Actual)
SponsorTechnische Universität Dresden (Other)
ConditionsNewly Diagnosed or Relapsed Acute Myeloid Leukemia
Datesstart 2011-02-01, primary completion 2013-09-01, completion 2013-09-01, first posted 2011-01-17, last updated 2013-09-18
Locations1 site in Germany

Related Papers Related Patents Related Grants Related Experts
AI Assistant Save
All trials for Newly Diagnosed or Relapsed Acute Myeloid Leukemia

-Summary

Myeloid Sarcoma (or granulocytic Sarcoma or Chloroma) is well defined by the WHO. However, there are currently no data about the prevalence, sites of occurence and thr prognostic value for patients with AML with this finding. Information about this condition is based on retrospective analyses since there have been no studies trying to define the role of myeloid sarcoma in AML so far. This observational trial will include adult patients with newly diagnosed and relapsed AML in order to perform 18FDG-PET-CT imaging prior to induction chemotherapy. Furthermore, a second 18FDG-PET-CT will be performed after induction chemotherapy to define the responsiveness of these tumors to chemotherapy. The primary endpoint of this study is the prevalence of 18FDG-PET-CT positive extramedullary AML manifestations (myeloid sarcoma) in patients with newly diagnosed or relapsed AML.

Expand all sections  ·  Collapse all

+Eligibility

Sex: All, ages: 18 Years to 80 Years

Inclusion Criteria:

* Patients with newly diagnosed or relapsed AML
* AML FAB M0-2, M4-7
* Signed informed consent after patient information
* Male and female patients with AML age 18-80
* 18FDG-PET-CT is available within a period of 5 days after diagnosis of AML

Exclusion Criteria:

* AML FAB M3 (Promyelocytic Leukemia)
* lacking willingness to cooperate
* pregnancy or insufficient contraception
* 18FDG-PET-CT is not available within a period of 5 days after diagnosis of AML
* Medical condition of the patients requires an immediated start of chemotherapy

+Locations (1)

FacilityCityCountryStatus
Medizinische Klinik und Poliklinik I, Universitätsklinikum Carl Gustav CarusDresden, SaxonyGermany

+Publications

  • Results publication: Stolzel F, Rollig C, Radke J, Mohr B, Platzbecker U, Bornhauser M, Paulus T, Ehninger G, Zophel K, Schaich M. (1)(8)F-FDG-PET/CT for detection of extramedullary acute myeloid leukemia. Haematologica. 2011 Oct;96(10):1552-6. doi: 10.3324/haematol.2011.045047. Epub 2011 Jun 17. PMID 21685468

My Notes